Rivaroxaban Clinical Trial Overview

The extensive evaluation of rivaroxaban makes it the most studied novel oral anticoagulant (OAC) in the world. No other novel OAC is approved for five indications in seven distinct areas of use, protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other novel OAC.*

Venous & Arterial Thromboembolism (VAT)



Completed Trials in Venous Thromboembolism (VTE)

RECORD 1 — PHASE III
Prevention of DVT and PE following elective total hip replacement*
4,541 patients | First approved in 2008

RECORD 2 — PHASE III
Prevention of DVT and PE following elective total hip replacement*
2,509 patients | First approved in 2008

RECORD 3 — PHASE III
Prevention of DVT and PE following elective total knee replacement*
2,531 patients | First approved in 2008

RECORD 4 — PHASE III
Prevention of DVT and PE following elective total knee replacement*
3,148 patients | First approved in 2008

MAGELLAN — PHASE III
DVT and PE Prevention in acutely ill, hospitalised patients**
8,101 patients | Primary efficacy endpoints met but no consistent positive benefit-risk balance

EINSTEIN DVT — PHASE III
Treatment of DVT and prevention of recurrent DVT or PE*
3,449 patients | First approved in 2011

EINSTEIN PE — PHASE III
Treatment of PE and the prevention of recurrent DVT and PE*
4,833 patients | First approved in 2012

EINSTEIN EXT — PHASE III
Long-term prevention of DVT and PE*
1,197 patients | First approved in 2011

XAMOS — OBSERVATIONAL
Prevention of DVT and PE following elective hip and knee surgery
17,413 patients | Results reported April 2012: Consistent with RECORD findings

Ongoing Venous Trials***

EINSTEIN CHOICE — PHASE III
Long-term, secondary prevention of DVT and PE
2,850 patients (planned) | Announced February 2014

EINSTEIN JUNIOR — PHASE III
Treatment and prevention of DVT and PE in paediatric populations
150 patients (planned) |Announced March 2014

MARINER — PHASE III
Prevention of DVT and PE in high-risk medically ill patients following hospital discharge
8,000 patients (planned) | Initiated April 2014

XALIA — OBSERVATIONAL
Patients with acute DVT
4,800 patients (planned) | Initiated June 2012

Completed Trials in Arterial Thrombosis and Thromboembolism

ROCKET AF — PHASE III
Prevention of stroke and systemic embolism in adult patients with non-valvular AF*
14,264 patients | First approved in 2011

J-ROCKET AF — PHASE III
Prevention of stroke and systemic embolism in adult patients with non-valvular AF*
1,280 patients | Approved in Japan in 2012

ATLAS ACS TIMI 51 — PHASE III
Secondary prevention after an ACS*
15,526 patients | First approved in 2013

X-VERT — PHASE IIIb
Stroke prevention in patients with non-valvular AF undergoing cardioversion
1,504 patients | Initiated October 2012 | Completed January 2014

X-PLORER — PHASE II
Thrombosis prevention in patients with CAD undergoing elective PCI**
108 patients | Initiated October 2011 | Completed March 2013

Ongoing Arterial Trials***

COMPASS — PHASE III
Prevention of major adverse cardiac events (MACE) in patients with CAD or PAD
20,000 patients (planned) | Initiated February 2013

COMMANDER HF — PHASE III
Reducing risk of death, MI or stroke in patients with chronic heart failure and significant CAD
5,000 patients (planned) | Initiated September 2013

PIONEER AF-PCI — PHASE IIIb
Evaluating the safety of rivaroxaban and VKAs in patients with non-valvular AF undergoing PCI with stent placement
2,100 patients (planned) | Initiated May 2013

VENTURE AF — PHASE IIIb
Stroke prevention in patients with non-valvular AF undergoing catheter ablation
200 patients (planned) | Initiated February 2013

XANTUS XANAP — OBSERVATIONAL
Real world studies in patients with non-valvular AF
XANTUS - 6,000 patients in Europe (planned) | Initiated June 2012
XANAP - 5,500 patients in Asia (planned) | Initiated January 2013

NAVIGATE ESUS — PHASE III
Secondary stroke prevention in patients with ESUS
7,000 patients (planned) | Announced August 2014

VOYAGER PAD — PHASE III
Prevention of thrombotic vascular complications in patients with PAD undergoing peripheral artery interventions
4,000 patients (planned) | Announced August 2014

GEMINI ACS 1 — PHASE II
Secondary prevention in patients after an ACS
2,000 - 3,000 patients (planned) | Announced August 2014

*Whilst licenses may differ from country to country, across all indications rivaroxaban is approved in more than 125 countries; **Rivaroxaban is not currently approved in this indication; ***Ongoing clinical trials include areas of unmet medical need where rivaroxaban is not currently approved